An Early Phase II Study of SI-01 in Dry Eye Patients - A randomized, double-masked, placebo-controlled, parallel-group comparative study to investigate the dose response and safety of SI-01 that is administered to dry eye patients (including post-corneal refractive surgery or post-cataract surgery patients) 4 times daily for 4 weeks
Latest Information Update: 07 Jan 2022
At a glance
- Drugs NRO 1 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Neuroptika
Most Recent Events
- 17 Aug 2020 According to a Neuroptika media release, the company plans to report topline data in the fourth quarter of this year.
- 17 Aug 2020 Status changed from recruiting to active, no longer recruiting according to a Neuroptika media release.
- 21 Jan 2020 New trial record